Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines

Oncology Reports

Volumn 35, Issue 5, 2016, Pages 2553-2560

  Kim, Jinkyoung ^a   Lee, Jiyun ^b   Jang, Soon Young ^b   Kim, Chungyeul ^a   Choi, Yoojin ^a   Kim, Aeree ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Anti estrogen therapy; Breast cancer; Estrogen receptor; Estrogen response element; Metformin; Tamoxifen resistance

Indexed keywords

ADENYLATE KINASE; ADENYLATE KINASE ALPHA; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; METFORMIN; MYC PROTEIN; PROGESTERONE RECEPTOR; PROTEIN PS2; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA, HUMAN; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; BREAST TUMOR; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; IC50; MCF-7 CELL LINE; METABOLISM; PHYSIOLOGY; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; METFORMIN; TAMOXIFEN; TRANSCRIPTIONAL ACTIVATION;

EID: 84964091199     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4675     Document Type: Article

References (38)

1. Ali S and Coombes RC: Estrogen receptor alpha in human breast cancer: Occurrence and significance. J Mammary Gland Biol Neoplasia 5: 271-281, 2000.
2. Hall JM, Couse JF and Korach KS: The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276: 36869-36872, 2001.
3. Couse JF and Korach KS: Estrogen receptor null mice: What have we learned and where will they lead us? Endocr Rev 20: 358-417, 1999.
4. Colditz GA: Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 90: 814-823, 1998.
5. Hankinson SE, Colditz GA and Willett WC: Towards an integrated model for breast cancer etiology: The lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 6: 213-218, 2004.
6. Uray IP and Brown PH: Chemoprevention of hormone receptornegative breast cancer: New approaches needed. In: Clinical Cancer Prevention. Springer, pp147-162, 2011.
7. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618, 1998.
8. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M and Cantley LC: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642-1646, 2005.
9. Bailey CJ and Turner RC: Metformin. N Engl J Med 334: 574-579, 1996.
10. Bowker SL, Majumdar SR, Veugelers P and Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258, 2006.
11. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305, 2005.
12. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res 3: 1451-1461, 2010.
13. Bosco JLF, Antonsen S, Sørensen HT, Pedersen L and Lash TL: Metformin and incident breast cancer among diabetic women: A population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 20: 101-111, 2011.
14. Beck E and Scheen AJ: Metformin, an antidiabetic molecule with anti-cancer properties. Rev Med Liege 68: 444-449, 2013 (In French).
15. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE and Thor AD: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8: 2031-2040, 2009.
16. Jiralerspong S, Gonzalez-Angulo AM and Hung M-C: Expanding the arsenal: Metformin for the treatment of triple-negative breast cancer? Cell Cycle 8: 2681-2684, 2009.
17. Marx J: Medicine. Cancer-suppressing enzyme adds a link to type 2 diabetes. Science 310: 1259-1259, 2005.
18. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M and Fantus IG: Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 8: 501-505, 2008.
19. Dowling RJ, Goodwin PJ and Stambolic V: Understanding the benefit of metformin use in cancer treatment. BMC Med 9: 33, 2011.
20. Markowska A, Pawałowska M, Filas V, Korski K, Gryboś M, Sajdak S, Olejek A, Bednarek W, Spiewankiewicz B, Lubin J, et al: Does Metformin affect ER, PR, IGF-1R, β-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer? Diabetol Metab Syndr 5: 76, 2013.
21. Yoo YA, Kim YH, Kim JS and Seo JH: The functional implications of Akt activity and TGF-beta signaling in tamoxifen-resistant breast cancer. Biochim Biophys Acta 1783: 438-447, 2008.
22. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE and Nicholson RI: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044, 2003.
23. Dauvois S, Danielian PS, White R and Parker MG: Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89: 4037-4041, 1992.
24. Clark GM, Osborne CK and McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2: 1102-1109, 1984.
25. Honig SF: Tamoxifen for the reduction in the incidence of breast cancer in women at high risk for breast cancer. Ann NY Acad Sci 949: 345-348, 2001.
26. Osborne CK and Schiff R: Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62: 233-247, 2011.
27. Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-10273, 2006.
28. Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-10812, 2007.
29. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y and Bost F: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586, 2008.
30. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B and Thompson CB: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752, 2007.
31. Gonzalez-Angulo AM and Meric-Bernstam F: Metformin: A therapeutic opportunity in breast cancer. Clin Cancer Res 16: 1695-1700, 2010.
32. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174, 2001.
33. Gullick WJ, Berger MS, Bennett PL, Rothbard JB and Waterfield MD: Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer 40: 246-254, 1987.
34. King CR, Kraus MH and Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974-976, 1985.
35. Riese DJ II, van Raaij TM, Plowman GD, Andrews GC and Stern DF: The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 15: 5770-5776, 1995.
36. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
37. Ross JS and Fletcher JA: The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells 16: 413-428, 1998.
38. Kim J, Lee J, Kim C, Choi J and Kim A: Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells. Tumour Biol: Nov 18, 2015 (Epub ahead of print).